Mazdutide

What it is

Mazdutide is an analogue of oxyntomodulin, a naturally occurring gut hormone that activates both the GLP-1 and glucagon receptors. That dual action is the same architecture as survodutide, and one arm short of retatrutide, which adds GIP.

The glucagon arm is what distinguishes this family from semaglutide. GLP-1 agonism suppresses appetite and slows gastric emptying, which reduces energy intake. Glucagon receptor activation raises energy expenditure and mobilises hepatic fat. One side of the equation each.

Why it is the notable one

It got approved first.

China's NMPA licensed mazdutide for chronic weight management in June 2025, making it the first GLP-1 and glucagon dual agonist to receive full regulatory authorisation for obesity anywhere. A second approval for glycaemic control in type 2 diabetes followed in September 2025.

That matters for how this site tiers things. Survodutide and retatrutide are further along in Western trials and better known in English-language communities, and both remain investigational. Mazdutide is approved, with published phase 3 data, and is barely discussed outside China.

Regulatory geography is not a proxy for evidence quality, but it is not nothing either. A drug that has satisfied a major regulator has been through a process that an investigational compound has not.

What the evidence shows

The phase 3 programme in Chinese adults, GLORY for obesity and DREAMS for diabetes, supported both approvals. A US-based phase 2 randomised placebo-controlled trial in adults with obesity or overweight has since been published, which is the step toward a Western filing.

Reported effects beyond weight include reductions in waist circumference, blood lipids, blood pressure, uric acid, liver enzymes and hepatic fat content. The hepatic effects are the ones most plausibly attributable to the glucagon arm rather than to weight loss alone.

Practical notes

• The trial population matters when reading the numbers. The phase 3 data is predominantly Chinese, at BMI thresholds set lower than Western criteria because obesity-related risk appears at lower BMI in East Asian populations. Efficacy figures do not transfer between populations as cleanly as people assume.
• The glucagon arm has a cost. Glucagon receptor activation raises heart rate and can raise hepatic glucose output. This is the same trade being watched in survodutide and retatrutide.
• Do not combine it with another incretin. Same receptor, same class, additive side effects, no additive benefit.

Side effects and warning signs

Commonly reported

• Nausea, most pronounced during titration
• Diarrhoea and vomiting
• Reduced appetite
• Transient rises in heart rate
• Injection-site reactions

Stop and get medical help

• Personal or family history of medullary thyroid carcinoma or MEN2
• Severe persistent abdominal pain radiating to the back
• Signs of gallbladder disease during rapid weight loss

Sources

1. Efficacy and safety of mazdutide in adults with obesity or overweight, US phase 2 RCT, Lancet Diabetes Endocrinol 2026trial
2. Mazdutide in predominantly Chinese adults with obesity or type 2 diabetes, systematic review and meta-analysisreview

From the community

Discussion for this compound concentrates in r/Semaglutide.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.